Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Vanderbilt-Ingram Cancer Center
City of Hope Medical Center
Case Comprehensive Cancer Center
Mayo Clinic
Icahn School of Medicine at Mount Sinai
Eli Lilly and Company
California Cancer Consortium
Eli Lilly and Company
Yale University
Children's Oncology Group
Indiana University
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Northwestern University
National Institutes of Health Clinical Center (CC)
NYU Langone Health
University of Arizona